Jump to main content
Jump to site search

Issue 1, 2013
Previous Article Next Article

Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells

Author affiliations

Abstract

In this paper, a targeted drug delivery system has been developed based on hyaluronic acid (HA) modified mesoporous silica nanoparticles (MSNs). HA-MSNs possess a specific affinity to CD44 over-expressed on the surface of a specific cancer cell line, HCT-116 (human colon cancer cells). The cellular uptake performance of fluorescently labelled MSNs with and without HA modification has been evaluated by confocal microscopy and fluorescence-activated cell sorter (FACS) analysis. Compared to bare MSNs, HA-MSNs exhibit a higher cellular uptake via HA receptor mediated endocytosis. An anticancer drug, doxorubicin hydrochloride (Dox), has been loaded into MSNs and HA-MSNs as drug delivery vehicles. Dox loaded HA-MSNs show greater cytotoxicity to HCT-116 cells than free Dox and Dox-MSNs due to the enhanced cell internalization behavior of HA-MSNs. It is expected that HA-MSNs have a great potential in targeted delivery of anticancer drugs to CD44 over-expressing tumors.

Graphical abstract: Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells

Back to tab navigation

Publication details

The article was received on 04 Aug 2012, accepted on 25 Sep 2012 and first published on 26 Sep 2012


Article type: Paper
DOI: 10.1039/C2NR32145A
Citation: Nanoscale, 2013,5, 178-183
  •   Request permissions

    Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells

    M. Yu, S. Jambhrunkar, P. Thorn, J. Chen, W. Gu and C. Yu, Nanoscale, 2013, 5, 178
    DOI: 10.1039/C2NR32145A

Search articles by author

Spotlight

Advertisements